JP2022538449A5 - - Google Patents

Info

Publication number
JP2022538449A5
JP2022538449A5 JP2021577871A JP2021577871A JP2022538449A5 JP 2022538449 A5 JP2022538449 A5 JP 2022538449A5 JP 2021577871 A JP2021577871 A JP 2021577871A JP 2021577871 A JP2021577871 A JP 2021577871A JP 2022538449 A5 JP2022538449 A5 JP 2022538449A5
Authority
JP
Japan
Prior art keywords
rilpivirine
pharmaceutically acceptable
acceptable salt
subject
equivalent amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021577871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538449A (ja
Filing date
Publication date
Priority claimed from US16/919,677 external-priority patent/US20210000823A1/en
Application filed filed Critical
Publication of JP2022538449A publication Critical patent/JP2022538449A/ja
Publication of JP2022538449A5 publication Critical patent/JP2022538449A5/ja
Withdrawn legal-status Critical Current

Links

JP2021577871A 2019-07-03 2020-07-03 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法 Withdrawn JP2022538449A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03
US62/870,413 2019-07-03
US16/919,677 US20210000823A1 (en) 2019-07-03 2020-07-02 Methods of treating hiv
US16/919,677 2020-07-02
PCT/EP2020/068913 WO2021001568A1 (en) 2019-07-03 2020-07-03 Methods of treating hiv in pediatric patients with rilpivirine

Publications (2)

Publication Number Publication Date
JP2022538449A JP2022538449A (ja) 2022-09-02
JP2022538449A5 true JP2022538449A5 (enExample) 2023-07-10

Family

ID=71579550

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577856A Withdrawn JP2022538338A (ja) 2019-07-03 2020-07-02 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
JP2021577871A Withdrawn JP2022538449A (ja) 2019-07-03 2020-07-03 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021577856A Withdrawn JP2022538338A (ja) 2019-07-03 2020-07-02 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Country Status (14)

Country Link
US (3) US20210000823A1 (enExample)
EP (2) EP3993799A1 (enExample)
JP (2) JP2022538338A (enExample)
KR (2) KR20220028049A (enExample)
CN (2) CN114126655A (enExample)
AU (2) AU2020300818A1 (enExample)
BR (2) BR112021026916A2 (enExample)
CA (1) CA3144307A1 (enExample)
IL (1) IL289457A (enExample)
JO (1) JOP20210347A1 (enExample)
MA (2) MA56449A (enExample)
MX (2) MX2022000060A (enExample)
PH (1) PH12021553288A1 (enExample)
WO (2) WO2021001508A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
JP2014500261A (ja) * 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
PT4070788T (pt) * 2015-06-30 2023-06-06 Gilead Sciences Inc Formulações farmacêuticas
US11065198B2 (en) * 2016-10-24 2021-07-20 Janssen Sciences Ireland Unlimited Company Dispersible compositions
CN110958883A (zh) * 2017-06-30 2020-04-03 Viiv保健公司 组合及其用途和疗法
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Similar Documents

Publication Publication Date Title
JP6196041B2 (ja) 大うつ病を有する患者において減量療法を提供する方法
KR20260046169A (ko) Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼
JP2022538449A5 (enExample)
JP2021004249A5 (enExample)
US20190151307A1 (en) Methods of treating patients co-infected with a virus and tuberculosis
JP2022538338A5 (enExample)
WO2019016679A1 (en) Combination drug therapy
US10758531B2 (en) Regimens and compositions for treating HIV infections and AIDS
AU2018239257B2 (en) HIV post-exposure prophylaxis
Dinh et al. An updated overview on long-acting therapeutics for the prevention and treatment of human immunodeficiency virus (HIV) from a perspective of pharmaceutics
RU2022102380A (ru) Способы лечения инфекции, вызванной вич, у пациентов детского возраста с применением рилпивирина
Kobayashi et al. A case of under-dosing after raltegravir formulation change in an elderly patient treated for HIV
CA3054822C (en) Hiv post-exposure prophylaxis
EP3664895A1 (en) Combinations and uses and treatments thereof
Francisco Data Released from Startmrk Study of Isentress Versus Efavirenz
KR20260057463A (ko) Hiv 캡시드 저해제의 투여 레지먼
Bowersox ACTG 343: three drugs better than two for maintaining HIV suppression
JP2019508399A (ja) 多くの治療を経験したｈｉｖ−１に感染した個体において使用するためのホステムサビル
JP2023527798A (ja) ＣＯＶＩＤ－１９（ＳＡＲＳ－ＣｏＶ－２）を含むＲＮＡウイルス感染を治療するための方法
EA049592B1 (ru) СПОСОБ ЛЕЧЕНИЯ РНК ВИРУСНЫХ ИНФЕКЦИЙ, В ТОМ ЧИСЛЕ COVID-19 (SARS-CoV-2)
SINGH et al. Novel Role of Combination Therapy of Lamivudine and Zidovudine Antiretroviral Drugs in Elevating The Efficiency
AU2020318808A1 (en) HIV pre-exposure prophylaxis
TW201726133A (zh) Ｈｉｖ成熟抑制劑調配物
JP2020529461A (ja) 組み合わせ並びにその使用及び治療